Last reviewed · How we verify
NCT03669939: TOWER
Toward Safer Opioid Prescribing for Chronic Pain in High Risk Populations
trial testing Communication Strategy in HIV Disease in 42 participants. Completed in 30 September 2020.
30 September 2020
Quick facts
| Lead sponsor | Icahn School of Medicine at Mount Sinai |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 42 |
| Start date | 5 October 2018 |
| Primary completion | 30 September 2020 |
| Estimated completion | 30 September 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Communication Strategy
- Standard of Care
Conditions studied
- HIV Disease — all drugs for HIV Disease →
- Chronic Pain — all drugs for Chronic Pain →
Sponsor
Icahn School of Medicine at Mount Sinai
Who can join
18 and older, any sex, with HIV Disease or Chronic Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overarching plan for TOWER is to develop and test an algorithmic version of the Center for Disease Control Guidelines (CDCG) tailored for a specific primary care setting, the HIV primary care clinic. This CDCG intervention incorporates communication and implementation strategies tailored for the HIV primary care setting, and enabled with technology (an app for use by patients and EMR tools for providers).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Toward Safer Opioid Prescribing in HIV care (TOWER): a mixed-methods, cluster-randomized trial.
Cedillo G, George MC, Deshpande R, Benn EKT, et al · · 2022 · cited 2× · PMID 35578356 · DOI 10.1186/s13722-022-00311-8
Verify or expand the search:
- PubMed search for NCT03669939
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Communication Strategy
Trials testing the same drug.
- NCT04180462 — Increasing Optimal Use of HPV Vaccination in Primary Care · NA · completed
Other recruiting trials for HIV Disease
Currently open trials in the same condition.
- NCT07292792 — The Unlocking PrEP Study: Integration of Peer Health Navigation Into Comprehensive Re-entry Services · recruiting
Other Icahn School of Medicine at Mount Sinai trials
Trials by the same sponsor.
- NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
- NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
- NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
- NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
- NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03669939 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
- Last refreshed: 9 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03669939.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing